Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adaptive Design, Phase 2-3, Randomized, Double-blind, Multicenter Study, Evaluating Safety, Efficacy, PK-PD of BIO101 in Prevention of Respiratory Deterioration in Hospitalized Patients With COVID-19 Pneumonia (Severe)

NCT04472728 is registered in ClinicalTrials.gov with Biophytis as lead sponsor.

NCT NCT04472728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04472728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adaptive Design, Phase 2-3, Randomized, Double-blind, Multicenter Study, Evaluating Safety, Efficacy, PK-PD of BIO101 in Prevention of Respiratory Deterioration in Hospitalized Patients With COVID-19 Pneumonia (Severe)
Lead sponsor
Biophytis
Phase
Phase 2/3
Overall status
Terminated
Start date
August 26, 2020
Completion date
June 6, 2022
Enrollment
238 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov2